Skip to main content

Table 1 Baseline characteristics

From: Addition of chemoradiotherapy to palliative chemotherapy in de novo metastatic nasopharyngeal carcinoma: a real-world study

 

Before matching

 

After matching

 
 

PCT + RT (N = 192) No. (%)

PCT + CCRT (N = 163) No. (%)

P-value

PCT + RT (N = 134) No. (%)

PCT + CCRT (N = 134) No. (%)

P-value

Age (years)

      

  < 45

102 (53.1)

81 (49.7)

0.590

75 (56.0)

69 (51.5)

0.462

  ≥ 45

90 (46.9)

82 (50.3)

 

59 (44.0)

65 (48.5)

 

Sex

      

 Male

163 (84.9)

141 (86.5)

0.781

112 (83.6)

117 (87.3)

0.386

 Female

29 (15.1)

22 (13.5)

 

22 (16.4)

17 (12.7)

 

Diagnosis period

      

 2000–2005

26 (13.5)

12 (7.4)

0.030

14 (10.4)

12 (9.0)

0.865

 2006–2011

66 (34.4)

45 (27.6)

 

33 (24.6)

36 (26.9)

 

 2012–2017

100 (52.1)

106 (65.0)

 

87 (64.9)

86 (64.2)

 

Pathology

      

 I-II

22 (11.5)

13 (8.0)

0.358

12 (9.0)

10 (7.5)

0.656

 III

170 (88.5)

150 (92.0)

 

122 (91.0)

124 (92.5)

 

Tumor category

      

 T1

7 (3.6)

8 (4.9)

0.012

6 (4.5)

2 (1.5)

0.539

 T2

33 (17.2)

13 (8.0)

 

15 (11.2)

13 (9.7)

 

 T3

95 (49.5)

72 (44.2)

 

65 (48.5)

67 (50.0)

 

 T4

57 (29.7)

70 (42.9)

 

48 (35.8)

52 (38.8)

 

Node category

      

 N0

6 (3.1)

5 (3.1)

0.830

3 (2.2)

5 (3.7)

0.231

 N1

39 (20.3)

31 (19.0)

 

24 (17.9)

28 (20.9)

 

 N2

79 (41.1)

75 (46.0)

 

50 (37.3)

60 (44.8)

 

 N3

68 (35.4)

52 (31.9)

 

57 (42.5)

41 (30.6)

 

Bone metastasis

      

 Absent

47 (24.5)

49 (30.1)

0.150

34 (25.4)

41 (30.6)

0.605

 Single

56 (29.2)

55 (33.7)

 

44 (32.8)

43 (32.1)

 

 Multiple

89 (46.4)

59 (36.2)

 

56 (41.8)

50 (37.3)

 

Liver metastasis

      

 Absent

154 (80.2)

128 (78.5)

0.915

114 (85.1)

104 (77.6)

0.264

 Single

17 (8.9)

15 (9.2)

 

8 (6.0)

14 (10.4)

 

 Multiple

21 (10.9)

20 (12.3)

 

12 (9.0)

16 (11.9)

 

Lung metastasis

      

 Absent

165 (85.9)

128 (78.5)

0.148

108 (80.6)

104 (77.6)

0.832

 Single

10 (5.2)

16 (9.8)

 

11 (8.2)

13 (9.7)

 

 Multiple

17 (8.9)

19 (11.7)

 

15 (11.2)

17 (12.7)

 

No. of metastatic organs

      

 None

10 (5.2)

7 (4.3)

0.441

8 (6.0)

5 (3.7)

0.375

 Single organ

157 (81.8)

127 (77.9)

 

109 (81.3)

105 (78.4)

 

 Multiple organs

25 (13.0)

29 (17.8)

 

17 (12.7)

24 (17.9)

 

Sites of organ metastasis

      

 Absent

10 (5.2)

7 (4.3)

0.226

8 (6.0)

5 (3.7)

0.527

 Single

62 (32.3)

67 (41.1)

 

47 (35.1)

54 (40.3)

 

 Multiple

120 (62.5)

89 (54.6)

 

79 (59.0)

75 (56.0)

 

Distant nodal metastasis

      

 Absent

170 (88.5)

141 (86.5)

0.806

116 (86.6)

115 (85.8)

1.000

 Single region

19 (9.9)

19 (11.7)

 

16 (11.9)

16 (11.9)

 

 Multiple regions

3 (1.6)

3 (1.8)

 

2 (1.5)

3 (2.2)

 

Metastatic type

      

 Distant metastasis without LN involvement

170 (88.5)

141 (86.5)

0.547

116 (86.6)

115 (85.8)

0.506

 Only distant LN metastasis

10 (5.2)

7 (4.3)

 

8 (6.0)

5 (3.7)

 

 Distant metastasis with LN involvement

12 (6.2)

15 (9.2)

 

10 (7.5)

14 (10.4)

 

No. of metastatic lesions

      

 Oligo

60 (31.2)

68 (41.7)

0.053

45 (33.6)

53 (39.6)

0.310

 Multiple

132 (68.8)

95 (58.3)

 

89 (66.4)

81 (60.4)

 

PCT regimen

      

 PF

69 (35.9)

43 (26.4)

0.052

48 (35.8)

36 (26.9)

0.157

 GP

12 (6.2)

4 (2.5)

 

7 (5.2)

4 (3.0)

 

 TP

46 (24.0)

39 (23.9)

 

35 (26.1)

31 (23.1)

 

 TPF

51 (26.6)

59 (36.2)

 

36 (26.9)

48 (35.8)

 

 Others

14 (7.3)

18 (11.0)

 

8 (6.0)

15 (11.2)

 

No. of PCT cycles

      

 1–3

35 (18.2)

41 (25.2)

0.232

23 (17.2)

33 (24.6)

0.317

 4–6

142 (74.0)

113 (69.3)

 

103 (76.9)

93 (69.4)

 

  > 6

15 (7.8)

9 (5.5)

 

8 (6.0)

8 (6.0)

 

Response to PCT

      

 CR

6 (3.1)

3 (1.8)

0.214

5 (3.7)

3 (1.8)

0.282

 PR

123 (64.1)

96 (58.9)

 

86 (64.2)

78 (58.2)

 

 SD

18 (9.4)

27 (16.6)

 

12 (9.0)

22 (16.4)

 

 Unknown

45 (23.4)

37 (22.7)

 

31 (23.1)

31 (23.1)

 

KPS before RT

      

 90

159 (82.8)

143 (87.7)

0.147

113 (84.3)

118 (88.1)

0.227

 80

9 (4.7)

10 (6.1)

 

7 (5.2)

9 (6.7)

 

 70

2 (1.0)

2 (1.2)

 

1 (0.7)

2 (1.5)

 

 Unknown

22 (11.5)

8 (4.9)

 

13 (9.7)

5 (3.7)

 

Technique of RT

      

 Conventional RT

67 (34.9)

28 (17.2)

 < 0.001

29 (21.6)

28 (17.2)

1.000

 IMRT

113 (58.9)

131 (80.4)

 

104 (77.6)

104 (77.6)

 

 Unknown

12 (6.2)

4 (2.5)

 

1 (0.7)

2 (1.5)

 

RT dose (Gy)

      

  < 60

11 (5.7)

2 (1.2)

0.020

1 (0.7)

2 (1.5)

1.000

  ≥ 60

179 (93.2)

161 (98.8)

 

133 (99.3)

132 (98.5)

 

 Unknown

2 (1.0)

0 (0.0)

 

0 (0.0)

0 (0.0)

 

Local treatment of metastatic sites

      

 No

128 (66.7)

102 (62.6)

0.489

81 (60.4)

86 (64.2)

0.529

 Yes

64 (33.3)

61 (37.4)

 

53 (39.6)

48 (35.8)

 
  1. PCT palliative chemotherapy, RT radiotherapy, CCRT concurrent chemoradiotherapy, No. number, LN lymph node, PF cisplatin plus 5-fluorouracil, GP gemcitabine plus cisplatin, TP cisplatin plus docetaxel, TPF cisplatin plus docetaxel plus 5-fluorouracil, CR complete response, PR partial response, SD stable disease, KPS Karnofsky performance score, IMRT intensity-modulated radiotherapy
Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us